Drug analysis: Keytruda

  • ID: 4462149
  • Drug Pipelines
  • 120 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the programmed death-1 (PD-1) co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival and induces apoptosis of tumor-specific T cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses. It has also been hypothesized that blocking the PD-1/PD-L1 interactions releases the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Keytruda: Colorectal cancer (CRC)
Keytruda: Head and neck cancer
Keytruda: Hepatocellular carcinoma (HCC)
Keytruda: Bladder cancer
Keytruda: Renal cell cancer (RCC)
Keytruda: Non-small cell lung cancer (NSCLC)
Keytruda: NHL: Diffuse large B-cell lymphoma (DLBCL)
Keytruda: Gastric cancer
Keytruda: Breast cancer: triple-negative
Keytruda: Melanoma
Keytruda: Multiple myeloma

List of Figures
Figure 1: Keytruda for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary for Keytruda in colorectal cancer
Figure 3: Drug assessment summary for Keytruda in colorectal cancer
Figure 4: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
Figure 5: Keytruda for head and neck cancer - SWOT analysis
Figure 6: Drug assessment summary of Keytruda for SCCHN
Figure 7: Drug assessment summary of Keytruda for SCCHN
Figure 8: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 9: Keytruda for HCC - SWOT analysis
Figure 10: Drug assessment summary of Keytruda for HCC
Figure 11: Drug assessment summary of Keytruda for HCC
Figure 12: Keytruda for urothelial bladder cancer - SWOT analysis
Figure 13: Drug assessment summary for Keytruda in urothelial bladder cancer
Figure 14: Drug assessment summary for Keytruda in urothelial bladder cancer
Figure 15: Keytruda for renal cell cancer - SWOT analysis
Figure 16: Drug assessment summary of Keytruda for renal cell cancer
Figure 17: Drug assessment summary of Keytruda for renal cell cancer
Figure 18: Keytruda for non-small cell lung cancer - SWOT analysis
Figure 19: Drug assessment summary for Keytruda in non-small cell lung cancer
Figure 20: Drug assessment summary for Keytruda in non-small cell lung cancer
Figure 21: Keytruda for diffuse large B-cell lymphoma - SWOT analysis
Figure 22: Drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 23: Drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 24: Keytruda for gastric cancer - SWOT analysis
Figure 25: Drug assessment summary for Keytruda in gastric cancer
Figure 26: Drug assessment summary for Keytruda in gastric cancer
Figure 27: Keytruda for triple-negative breast cancer - SWOT analysis
Figure 28: Drug assessment summary of Keytruda for triple-negative breast cancer
Figure 29: Drug assessment summary of Keytruda for triple-negative breast cancer
Figure 30: Keytruda in melanoma - SWOT analysis
Figure 31: Drug assessment summary of Keytruda for melanoma
Figure 32: Drug assessment summary of Keytruda for melanoma
Figure 33: Keytruda for multiple myeloma - SWOT analysis
Figure 34: Drug assessment summary of Keytruda in multiple myeloma
Figure 35: Drug assessment summary of Keytruda in multiple myeloma

List of Tables
Table 1: Keytruda drug profile
Table 2: Keytruda Phase III trial in colorectal cancer
Table 3: Keytruda early-phase data in colorectal cancer
Table 4: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016-25
Table 6: Keytruda drug profile
Table 7: Keytruda pivotal trial data in head and neck cancer
Table 8: Keytruda ongoing late-phase trials in head and neck cancer
Table 9: Keytruda early-phase data in head and neck cancer
Table 10: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 11: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 12: Keytruda drug profile
Table 13: Keytruda Phase II and Phase III trials in HCC
Table 14: Keytruda drug profile
Table 15: Keytruda pivotal trial data in urothelial bladder cancer
Table 16: Keytruda ongoing late-phase trials in urothelial bladder cancer
Table 17: Keytruda early-phase data in urothelial bladder cancer
Table 18: Keytruda drug profile
Table 19: Keytruda Phase III trial in renal cell cancer
Table 20: Keytruda drug profile
Table 21: Keytruda pivotal trial data in non-small cell lung cancer
Table 22: Keytruda ongoing late-phase clinical trials in non-small cell lung cancer
Table 23: Keytruda drug profile
Table 24: Keytruda drug profile
Table 25: Keytruda early- and late-phase trials in gastric cancer
Table 26: Keytruda early-phase data in gastric cancer
Table 27: Keytruda drug profile
Table 28: Keytruda Phase III trial in triple-negative breast cancer
Table 29: Keytruda Phase Ib data in triple-negative breast cancer
Table 30: Keytruda drug profile
Table 31: Overview of pivotal trial data for Keytruda in melanoma
Table 32: Keytruda ongoing clinical trials in melanoma
Table 33: Keytruda drug profile
Table 34: Keytruda Phase III trials in multiple myeloma
Table 35: Keytruda early-phase data in multiple myeloma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll